{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-030048","form_type":"8-K","ticker":"SMNR","cik":"0001913577","company_name":"Semnur Pharmaceuticals, Inc.","filed_at":"2025-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.456909+00:00","generated_at":"2026-05-23T18:36:40.975822+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"confidence":"high","headline":"Denali Capital receives Nasdaq delisting determination; must appeal by April 9 or face suspension","bullets":["On April 2, 2025, Nasdaq staff determined Denali failed to meet MVLS, total assets, and public float rules.","Company must appeal by April 9, 2025 to avoid delisting; if no appeal, trading suspended April 11, 2025.","Company expects to trade on OTC market after delisting; plans to remain a reporting company.","Delisting not expected to immediately impact planned business combination with Semnur Pharmaceuticals."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-030048","json":"https://secwatch.observer/filing/0001213900-25-030048.json","markdown":"https://secwatch.observer/filing/0001213900-25-030048.md","text":"https://secwatch.observer/filing/0001213900-25-030048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1913577/000121390025030048/0001213900-25-030048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1913577/000121390025030048/ea0237665-8k425_denali.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:36:40.975822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}